{"id":"long-gnrh-agonist-hrt","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Night sweats"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Long-acting GnRH agonists desensitize the pituitary gland, leading to sustained suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which dramatically reduces estrogen and progesterone levels. The subsequent HRT component replaces these hormones in a controlled manner to alleviate vasomotor and other menopausal symptoms while maintaining the therapeutic benefits of hormone suppression. This approach is typically used in conditions where estrogen suppression is beneficial (such as endometriosis or certain gynecological conditions) while mitigating the adverse effects of hypoestrogenism.","oneSentence":"A combination therapy that suppresses gonadotropin-releasing hormone (GnRH) signaling to reduce sex hormone production, followed by hormone replacement therapy (HRT) to manage menopausal symptoms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:23.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Endometriosis with menopausal symptom management"},{"name":"Uterine fibroids (leiomyomas) with hormone replacement"}]},"trialDetails":[{"nctId":"NCT05189873","phase":"PHASE3","title":"GnRH Agonist Plus Hormone Replacement Therapy vs Hormone Replacement Therapy on IVF Outcomes","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2021-06-10","conditions":"Polycystic Ovary Syndrome, Infertility, Female","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Long GnRH agonist + HRT","genericName":"Long GnRH agonist + HRT","companyName":"Tehran University of Medical Sciences","companyId":"tehran-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination therapy that suppresses gonadotropin-releasing hormone (GnRH) signaling to reduce sex hormone production, followed by hormone replacement therapy (HRT) to manage menopausal symptoms. Used for Endometriosis with menopausal symptom management, Uterine fibroids (leiomyomas) with hormone replacement.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}